UBT251 Injection Phase II (Type 2 Diabetes Mellitus) Study

NCT07163624 · Completed

Last updated 2026-05-28

This clinical trial is testing the safety and effectiveness of the experimental drug UBT251 injection in adults with type 2 diabetes to see how it affects their blood sugar levels over 24 weeks.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 211 people

Who can join Ages 18–75 · all sexes

Timeline Started 2025-03 · est. completion 2025-12

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT07163624 ↗

Description as written by the study sponsor.

The purpose of this study is to evaluate the efficacy of UBT251 injection after 24 weeks of continuous administration in patients with type 2 diabetes mellitus and to recommend the dosing regimen for the Phase III clinical trial.

Treatments tested

UBT251 Injection 2.0 mg and UBT251 Injection Placebo Drug

UBT251 Injection and UBT251 Injection Placebo once weekly
UBT251 Injection 4.0 mg (ID 0.5 mg) and UBT251 Injection Placebo Drug

UBT251 Injection and UBT251 Injection Placebo once weekly
UBT251 Injection 4.0 mg (ID 1.0 mg) and UBT251 Injection Placebo Drug

UBT251 Injection and UBT251 Injection Placebo once weekly
UBT251 Injection 6.0 mg and UBT251 Injection Placebo Drug

UBT251 Injection and UBT251 Injection Placebo once weekly
Semaglutide Injection (Ozempic®) Drug

Semaglutide Injection (Ozempic®) once weekly

Main thing measured	Change From Baseline in HbA1c at Week 24
Sponsor	The United Bio-Technology (Hengqin) Co., Ltd.
Conditions studied	Type 2 Diabetes Mellitus (T2DM)
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07163624 ↗